drugset / Trial / NCT03913949
A Study to Evaluate the Safety,PK and PD of APG-2575 in Patients With Hematologic Malignancies
Phase 1
Active not recruiting
74 enrolled
Ascentage Pharma Group Inc.
Suzhou Yasheng Pharmaceutical Co., Ltd. · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to assess the safety, tolerability, pharmacokinetic and pharmacodynamic properties of APG-2575 in patients with relapse or refractory chronic lymphocytic leukemia and non-hodgkin's lymphoma.
Timeline
- Start
- 2019-06-03
- Primary completion
- 2024-10-20
- Completion
- 2026-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | APG-2575 | Small molecule | 20 mg | Oral |
| Subject | APG-2575 | Small molecule | 50 mg | Oral |
| Subject | APG-2575 | Small molecule | 100 mg | Oral |
| Subject | APG-2575 | Small molecule | 200 mg | Oral |
| Subject | APG-2575 | Small molecule | 400 mg | Oral |
| Subject | APG-2575 | Small molecule | 600 mg | Oral |
| Subject | APG-2575 | Small molecule | 800 mg | Oral |